What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?

키워드

참고문헌 (15)

1. Sung H, "Global Cancer Statistics 2020 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185Countries", CA Cancer J Clin, 71, pp.209~249 (2021)
2. Young Eun Chon, "Hepatocellular carcinoma statistics in South Korea", Clinical and Molecular Hepatology, 27(3), pp.512~514 (2021), 대한간학회[DOI]
3. Korean Liver Cancer Study Group and National Cancer Center, Korea, "Practice guidelines for management of hepatocellular carcinoma 2009", Korean J Hepatol, 15, pp.391~423 (2009)
4. 한국 간 암 스터디그룹, "2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma", Gut and Liver, 9(3), pp.267~317 (2015), 거트앤리버 소화기연관학회협의회
5. Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
6. Korean Liver Cancer Association (KLCA), "2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma", Clinical and Molecular Hepatology, 28(4), pp.583~705 (2022), 대한간학회
7. Myung Ji Goh, "Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective", Clinical and Molecular Hepatology, 29(2), pp.197~205 (2023), 대한간학회
8. Won Sohn, "Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease", Clinical and Molecular Hepatology, 28(4), pp.851~863 (2022), 대한간학회
9. Bo Hyun Kim, "Surveillance for hepatocellular carcinoma: It is time to move forward", Clinical and Molecular Hepatology, 28(4), pp.810~813 (2022), 대한간학회
10. Kim BK, "Applicability of BCLC stage for prognostic stratification in comparison with other staging systems : single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma", Liver Int, 32, pp.1120~1127 (2012)
11. 김도영, "Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region", Clinical and Molecular Hepatology, 29(2), pp.277~292 (2023), 대한간학회
12. 이선영, "Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging", Clinical and Molecular Hepatology, 26(3), pp.340~351 (2020), 대한간학회[DOI]
13. Joseph C Ahn, "Systemic therapy in advanced hepatocellular carcinoma", Clinical and Molecular Hepatology, 29(2), pp.516~519 (2023), 대한간학회
14. Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
15. Abou-Alfa GK, "Phase 3 randomized, open-label, multicenter study of tremelimumab(T)and durvalumab(D)as first-line therapy in patients(pts)with unresectable hepatocellular carcinoma(uHCC) : HIMALAYA", J Clin Oncol, 40(4 suppl), pp.379~ (2022)

관련 논문AI추천